220 related articles for article (PubMed ID: 31337255)
41. Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Baxter JS; Brough R; Krastev DB; Song F; Sridhar S; Gulati A; Alexander J; Roumeliotis TI; Kozik Z; Choudhary JS; Haider S; Pettitt SJ; Tutt ANJ; Lord CJ
Mol Oncol; 2024 Feb; 18(2):369-385. PubMed ID: 37866880
[TBL] [Abstract][Full Text] [Related]
42. Lysine-52 stabilizes the MYC oncoprotein through an SCF
De Melo J; Kim SS; Lourenco C; Penn LZ
Oncogene; 2017 Dec; 36(49):6815-6822. PubMed ID: 28806398
[TBL] [Abstract][Full Text] [Related]
43. Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development.
Kwon YW; Kim IJ; Wu D; Lu J; Stock WA; Liu Y; Huang Y; Kang HC; DelRosario R; Jen KY; Perez-Losada J; Wei G; Balmain A; Mao JH
Mol Cancer Res; 2012 Jun; 10(6):834-44. PubMed ID: 22513362
[TBL] [Abstract][Full Text] [Related]
44. The SCF-FBXW7 E3 ubiquitin ligase triggers degradation of histone 3 lysine 4 methyltransferase complex component WDR5 to prevent mitotic slippage.
Hänle-Kreidler S; Richter KT; Hoffmann I
J Biol Chem; 2022 Dec; 298(12):102703. PubMed ID: 36395886
[TBL] [Abstract][Full Text] [Related]
45. Early growth response-1 is a new substrate of the GSK3β-FBXW7 axis.
Yin L; Zhang J; Sun Y
Neoplasia; 2022 Dec; 34():100839. PubMed ID: 36240645
[TBL] [Abstract][Full Text] [Related]
46. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
Chen X; Li XY; Long M; Wang X; Gao ZW; Cui Y; Ren J; Zhang Z; Liu C; Dong K; Zhang H
Neoplasma; 2018; 65(2):201-209. PubMed ID: 29534580
[TBL] [Abstract][Full Text] [Related]
47. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer.
Calcagno DQ; Freitas VM; Leal MF; de Souza CR; Demachki S; Montenegro R; Assumpção PP; Khayat AS; Smith Mde A; dos Santos AK; Burbano RR
BMC Gastroenterol; 2013 Sep; 13():141. PubMed ID: 24053468
[TBL] [Abstract][Full Text] [Related]
48. CRL2
Motomura S; Yumimoto K; Tomonaga T; Nakayama KI
Oncogene; 2024 Jun; 43(25):1917-1929. PubMed ID: 38698266
[TBL] [Abstract][Full Text] [Related]
49. FBXW7 is involved in Aurora B degradation.
Teng CL; Hsieh YC; Phan L; Shin J; Gully C; Velazquez-Torres G; Skerl S; Yeung SC; Hsu SL; Lee MH
Cell Cycle; 2012 Nov; 11(21):4059-68. PubMed ID: 23095493
[TBL] [Abstract][Full Text] [Related]
50. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
51. The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function.
Reiterer V; Figueras-Puig C; Le Guerroue F; Confalonieri S; Vecchi M; Jalapothu D; Kanse SM; Deshaies RJ; Di Fiore PP; Behrends C; Farhan H
EMBO J; 2017 Feb; 36(3):260-273. PubMed ID: 28007894
[TBL] [Abstract][Full Text] [Related]
52. Clinical significance of FBXW7 loss of function in human cancers.
Fan J; Bellon M; Ju M; Zhao L; Wei M; Fu L; Nicot C
Mol Cancer; 2022 Mar; 21(1):87. PubMed ID: 35346215
[TBL] [Abstract][Full Text] [Related]
53. mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.
Koo J; Yue P; Deng X; Khuri FR; Sun SY
Mol Cell Biol; 2015 Jul; 35(13):2344-55. PubMed ID: 25918246
[TBL] [Abstract][Full Text] [Related]
54.
Liu F; Zou Y; Wang F; Yang B; Zhang Z; Luo Y; Liang M; Zhou J; Huang O
Genet Test Mol Biomarkers; 2019 Jun; 23(6):409-417. PubMed ID: 31161818
[No Abstract] [Full Text] [Related]
55. Tumor-suppressor Fbxw7 targets SIK2 for degradation to interfere with TORC2-AKT signaling in pancreatic cancer.
Zhang MX; Wang H; Sun GP
Cell Biol Int; 2020 Sep; 44(9):1900-1910. PubMed ID: 32437091
[TBL] [Abstract][Full Text] [Related]
56. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL.
Matsuoka S; Oike Y; Onoyama I; Iwama A; Arai F; Takubo K; Mashimo Y; Oguro H; Nitta E; Ito K; Miyamoto K; Yoshiwara H; Hosokawa K; Nakamura Y; Gomei Y; Iwasaki H; Hayashi Y; Matsuzaki Y; Nakayama K; Ikeda Y; Hata A; Chiba S; Nakayama KI; Suda T
Genes Dev; 2008 Apr; 22(8):986-91. PubMed ID: 18367647
[TBL] [Abstract][Full Text] [Related]
57. Stringent Control of NFE2L3 (Nuclear Factor, Erythroid 2-Like 3; NRF3) Protein Degradation by FBW7 (F-box/WD Repeat-containing Protein 7) and Glycogen Synthase Kinase 3 (GSK3).
Kannan MB; Dodard-Friedman I; Blank V
J Biol Chem; 2015 Oct; 290(43):26292-302. PubMed ID: 26306035
[TBL] [Abstract][Full Text] [Related]
58. FBXW7 and DNA copy number instability.
Byrd KN; Huey B; Roydasgupta R; Fridlyand J; Snijders AM; Albertson DG
Breast Cancer Res Treat; 2008 May; 109(1):47-54. PubMed ID: 17588203
[TBL] [Abstract][Full Text] [Related]
59. Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas.
Jen KY; Song IY; Banta KL; Wu D; Mao JH; Balmain A
Blood; 2012 Jan; 119(3):805-9. PubMed ID: 22117044
[TBL] [Abstract][Full Text] [Related]
60. G
Giráldez S; Galindo-Moreno M; Limón-Mortés MC; Rivas AC; Herrero-Ruiz J; Mora-Santos M; Sáez C; Japón MÁ; Tortolero M; Romero F
FASEB J; 2017 Jul; 31(7):2925-2936. PubMed ID: 28360195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
